{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:39:44Z","timestamp":1760888384029},"reference-count":36,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Osteonecrosis of the jaws (ONJ) is a well known side effect of bisphosphonate therapies in patients with multiple myeloma or other malignancies. Its real incidence is still undetermined, and only few cases of ONJ in patients taking bisphosphonates for non-oncologic diseases have been reported. It was postulated that the clinical features, predisposing factors, and treatment outcome of this subset of patients might be different from those of oncologic patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Over a 4 year period, a total of 102 bisphosphonate-treated patients affected by ONJ were identified. Among these, 24 patients underwent bisphosphonate therapy for non-neoplastic disease and their profile was analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>In this study cohort, bisphosphonates had been administered mainly for postmenopausal osteoporosis (20\/24 patients, 83.3%), the duration of therapy until presentation of ONJ ranging from 11 to 40 months and the most common triggering event being dentoalveolar surgery. All patients were nonsmokers; 6 manifested multiple ONJ lesions and only 3 of them had possible comorbidities. Surgical debridement was performed in 19 patients for a total of 22 lesions, which were individually considered in the followup. The latter showed complete remission of ONJ in 21\/22 lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Although it might be considered a rare condition in non-oncologic patients, ONJ is a harmful side effect of bisphosphonate therapies. Clinicians must be aware of this entity, inform patients of the risks related to dental surgery, and possibly undertake adequate preventive measures.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.090455","type":"journal-article","created":{"date-parts":[[2009,11,3]],"date-time":"2009-11-03T02:35:31Z","timestamp":1257215731000},"page":"2780-2787","source":"Crossref","is-referenced-by-count":29,"title":["Osteonecrosis of the Jaw Correlated to Bisphosphonate Therapy in Non-oncologic Patients: Clinicopathological Features of 24 Patients"],"prefix":"10.3899","volume":"36","author":[{"given":"GIANFRANCO","family":"FAVIA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GIOVANNI PIETRO","family":"PILOLLI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EUGENIO","family":"MAIORANO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2009,11,2]]},"reference":[{"key":"2018112909213620000_36.12.2780.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(02)00079-8"},{"key":"2018112909213620000_36.12.2780.2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118722"},{"key":"2018112909213620000_36.12.2780.3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg401"},{"key":"2018112909213620000_36.12.2780.4","first-page":"3890","article-title":"Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices","volume":"57","author":"Boissier","year":"1997","journal-title":"Cancer Res"},{"key":"2018112909213620000_36.12.2780.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0808738"},{"key":"2018112909213620000_36.12.2780.6","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932030-00004"},{"key":"2018112909213620000_36.12.2780.7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-90004-28"},{"key":"2018112909213620000_36.12.2780.8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0159"},{"key":"2018112909213620000_36.12.2780.9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0714.2007.00540.x","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review","volume":"36","author":"Hewitt","year":"2007","journal-title":"J Oral Pathol Med"},{"key":"2018112909213620000_36.12.2780.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2006.10.008"},{"key":"2018112909213620000_36.12.2780.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2005.08.001"},{"key":"2018112909213620000_36.12.2780.12","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.14219\/jada.archive.2006.0355","article-title":"Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations","volume":"137","year":"2006","journal-title":"J Am Dent Assoc"},{"key":"2018112909213620000_36.12.2780.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.01.003"},{"key":"2018112909213620000_36.12.2780.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tripleo.2006.06.004"},{"key":"2018112909213620000_36.12.2780.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"2018112909213620000_36.12.2780.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(03)00328-8"},{"key":"2018112909213620000_36.12.2780.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2007.08.003"},{"key":"2018112909213620000_36.12.2780.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2004.02.004"},{"key":"2018112909213620000_36.12.2780.19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21130"},{"key":"2018112909213620000_36.12.2780.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.99.132"},{"key":"2018112909213620000_36.12.2780.21","first-page":"111","article-title":"Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy","volume":"71","author":"Melo","year":"2005","journal-title":"J Can Dent Assoc"},{"key":"2018112909213620000_36.12.2780.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200507073530120"},{"key":"2018112909213620000_36.12.2780.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.8670"},{"key":"2018112909213620000_36.12.2780.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0460-7"},{"key":"2018112909213620000_36.12.2780.25","doi-asserted-by":"publisher","DOI":"10.1210\/er.2001-9002"},{"key":"2018112909213620000_36.12.2780.26","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/17453670610013213","article-title":"Postoperative clodronate decreases prosthetic migration: 4-year follow-up of a randomized radiostereometric study of 50 total knee patients","volume":"77","author":"Hilding","year":"2006","journal-title":"Acta Orthop"},{"key":"2018112909213620000_36.12.2780.27","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0121"},{"key":"2018112909213620000_36.12.2780.28","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0707onj"},{"key":"2018112909213620000_36.12.2780.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tripleo.2006.10.010"},{"key":"2018112909213620000_36.12.2780.30","doi-asserted-by":"publisher","DOI":"10.1902\/jop.2007.060239"},{"key":"2018112909213620000_36.12.2780.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2005.07.010"},{"key":"2018112909213620000_36.12.2780.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0384-2"},{"key":"2018112909213620000_36.12.2780.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.2006.00841.x"},{"key":"2018112909213620000_36.12.2780.34","first-page":"E755","article-title":"Oral implants in patients receiving bisphosphonates: a review and update","volume":"13","author":"Serra","year":"2008","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"2018112909213620000_36.12.2780.35","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.joms.2008.01.054","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"66","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"2018112909213620000_36.12.2780.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2008.01.012"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.090455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T17:34:57Z","timestamp":1543512897000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.090455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,2]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.3899\/jrheum.090455"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.090455","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,2]]}}}